Regulus Therapeutics Inc. (NASDAQ: RGLS) revealed top-line results from the primary endpoint analysis of one of its ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Maybe the third time's the charm? Regulus Therapeutics is once again shuffling its pipeline and sliding a new kidney disease candidate into the high-priority queue, hoping for better fortunes after a ...
Regulus Therapeutics's stock price closed at $1.0600. It is down -13.8200% in the last 3 months and down -63.2700% in the last 12 months. Regulus Therapeutics saw 1 positive EPS revisions and 0 ...
Shares of Regulus Therapeutics RGLS increased 16.87% during market hours on Sep 12 after the company announced positive top-line safety and pharmacokinetics data from its phase I single ascending dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results